Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.

"Conflict of Interest Martin Metz has received honoraria as speakers and/or consultant from Aralez, Argenx, Bayer, Celgene, Moxie, Novartis, Roche, Sanofi, and Uriach. Zahava Vadasz has received honoraria as speaker from Novartis, RAFA, and Sanofi; and has received research grants supported from Novartis. Emek Kocatürk has received honoraria as speaker and consultant for Bayer, Novartis, and Sanofi. Ana M Giménez-Arnau has served as medical advisor for Uriach Pharma, Genentech, Novartis, FAES, GlaxoSmithKline (GSK), and Sanofi; has received research grants from Uriach Pharma, Novartis, and Instituto Carlos III—La Federación Española de Enfermedades Raras (FEDER); and is involved in educational activities for Uriach Pharma, Novartis, Genentech, Menarini, LEO Pharma, GSK, Merck Sharp & Dohme, Almirall, and Sanofi."

"Funding Information Editorial and medical writing support was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with the Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3)."